US Stock Futures Edge Higher Ahead Of Economic Data

Loading...
Loading...
Pre-open movers
US stock futures traded slightly higher in early pre-market trade. Data on consumer spending for January will be released at 8:30 a.m. ET, while the Markit PMI manufacturing index for February will be released at 9:45 a.m. ET. The ISM manufacturing composite index for February and construction spending data for January will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average climbed 7 points to 18,134.00, while the Standard & Poor's 500 index futures rose 0.30 points to 2,103.10. Futures for the Nasdaq 100 index gained 5.25 points to 4,447.75.
A Peek Into Global Markets
European markets were lower today, with the Spanish Ibex Index dropping 0.21%, STOXX Europe 600 Index falling 0.43% and German DAX 30 index dropping 0.03%. French CAC 40 Index dipped 0.71% and London's FTSE 100 Index fell 0.12%. In Asian markets, Japan's Nikkei Stock Average rose 0.15%, Hong Kong's Hang Seng Index climbed 0.26%, China's Shanghai Composite Index climbed 0.78% and India's BSE Sensex jumped 0.33%.
Broker Recommendation
Analysts at Atlantic Equities downgraded International Business Machines Corporation
IBM
from Neutral to Underweight, according to sources. IBM's shares climbed 0.67% to close at $161.94 on Friday.
Breaking news
    NXP Semiconductors N.V. NXPI and Freescale Semiconductor, Ltd. FSL today announced that they have entered into a definitive agreement under which NXP will merge with Freescale in a transaction which values the combined enterprise at just over $40 billion. To read the full news, click here. Nielsen N.V. NLSN today announced that Valcon Acquisition Holding (Luxembourg) S.à r.l. intends to offer for sale in an underwritten secondary offering 8,000,000 shares of its common stock pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission. To read the full news, click here. Shire plc SHPG announced today that the company has submitted a New Drug Application (NDA) with the U. S. Food and Drug Administration for its investigational compound lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. To read the full news, click here. Alkermes plc ALKS today announced a new drug candidate, ALKS 7119, for the treatment of agitation in patients with Alzheimer's disease, major depressive disorder (MDD) and other central nervous system (CNS) indications. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsAtlantic EquitiesUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...